Esaxerenone is under clinical development by Daiichi Sankyo and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Esaxerenone’s likelihood of approval (LoA) and phase transition for Diabetic Hypertension took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Esaxerenone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Esaxerenone overview

Esaxerenone (Minnebro) is an anti-hypertensive agent. It is formulated as tablets for oral route of administration. Minnebro is indicated for the treatment of hypertension in adults.

Esaxerenone (CS-3150, XL550) is under development for the treatment of diabetic hypertension. It was also under development for diabetic nephropathy and microalbuminuria in type 2 diabetic patients.

Daiichi Sankyo overview

Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

Quick View Esaxerenone LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Esaxerenone
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.